Clinical study on thalidomide alone or combined with dexamethasone in the treatment of relapsed and refractory multiple myeloma
- VernacularTitle:沙利度胺治疗难治性复发性多发性骨髓瘤的临床研究
- Author:
Hua JIANG
;
Huiyan JIN
;
Dongxing WANG
- Publication Type:Journal Article
- Keywords:
multiple myeloma;
thalidomide;
dexamethasone;
chemotherapy
- From:China Oncology
1998;0(01):-
- CountryChina
- Language:Chinese
-
Abstract:
Purpose:To investigate the effects and side- ef fects of thalidomide in the treatment of relapsed and refractory multiple myelom a (MM).Methods:There were thirteen men and two women aged 33～7 6 (median 58) years in thalidomide alone group. Two cases were newly diagnosed my eloma; twelve of them were refractory myeloma, including three relapsed cases wh o had experienced autologous peripheral blood stem cell transplantation (AutoPBS CT); another one is primary plasma cell leukemia. The starting dose was 100mg/d, escalating up to a maximum of 800mg/d. The combination group included twenty me n and seven women aged 40～81 (median 56) years of which case was newly diagnose d myeloma; twenty-five cases were refractory myeloma, two of whom relapsed after AutoPBSCT; another one was primary plasma cell leukemia. Dexamethasone 40mg/d w as used at d 1-4 , d 9-12 , d 17-20 when the dose of thalidomide increased to 400mg/d. Each cycle lasted for one month.Results: The total response rate was 42.9% and 57.7% in thalidomide alone group and in co mbination group, respectively. The response rate in refractory patients was 33.3 % and 44.0% in thalidomide alone group and in combination group, respectively. T here was no difference between the two groups in response rates. Both of the two groups had side effects of constipation and skin rash, etc. in different degree s but usually tolerable. Conclusions:Both thalidomide alone and thalidomide combined with dexamethasone was effective in the treatment of relap sed and refractory MM.
